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Background: Sarcoidosis is a granulomatous disorder of unknown etiology. The term of immunoangiostasis has
been addressed by various studies as potentially involved in the disease pathogenesis. The aim of the study was to
investigate the expression of the master regulator of angiogenesis hypoxia inducible factor (HIF)-1a – vascular
endothelial growth factor (VEGF)- inhibitor of growth factor 4-(ING4) - axis within sarcoid granuloma.
Methods: A total of 37 patients with sarcoidosis stages II-III were recruited in our study. Tissue microarray
technology coupled with immunohistochemistry analysis were applied to video-assisted thoracoscopic surgery
(VATS) lung biopsy samples collected from 37 sarcoidosis patients and 24 controls underwent surgery for benign
lesions of the lung. Computerized image analysis was used to quantify immunohistochemistry results. qRT-PCR was
used to assess HIF-1a and ING4 expression in 10 sarcoidosis mediastinal lymph node and 10 control lung samples.
Results: HIF-1a and VEGF-ING4 expression, both in protein and mRNA level, was found to be downregulated and
upregulated, respectively, in sarcoidosis samples compared to controls. Immunohistochemistry coupled with
computerized image analysis revealed minimal expression of HIF-1a within sarcoid granulomas whereas an
abundant staining of ING4 and VEGF in epithelioid cells was also visualized.
Conclusions: Our data suggest an impairment of the HIF-1a – VEGF axis, potentialy arising by ING4 overexpression
and ultimately resulting in angiostasis and monocyte recruitment within granulomas. The concept of
immunoangiostasis as a possible protection mechanism against antigens of infectious origin needs further research
to be verified.Background
Sarcoidosis is an immunologic, granulomatous disorder
affecting multiple systems. It is pathologically character-
ized by the presence of non-caseating granulomas in
involved organs [1]. Lung, including the mediastinal and
hilar lymph nodes is the most common site of disease
manifestation [2,3]. The prevalence of the disease is esti-
mated at 10 to 20 per 100.000 population [2,3]. Its* Correspondence: atzouvelekis@yahoo.gr
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distribution, and reproduction in any mediumpathogenesis is unknown, although various factors in-
cluding environmental and occupational exposures, in-
fectious agents and genetic susceptibility have been
implicated [4-6].
Various studies suggest that angiogenic and angiostatic
factors contribute to the pathogenesis of Sarcoidosis
[4,5,7-9]. Seminal observations by Strieter et al. [10]
implicated angiogenesis in the pathogenesis of granu-
lomatous and fibrotic lung disorders. A regulation of T
cell migration and activation by angiostatic chemokines,
such as IP-10, resulting in granulomas formation has
also been demonstrated [10]. Further extending thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Data are presented as median (range), No (total) or mean ± SD, unless stated
otherwise.
Abbreviations: DLCO: Diffuse lung capacity for carbon monoxide, FEV1: Forced
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capacity
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profile between sarcoidosis and idiopathic pulmonary fi-
brosis (IPF) has been recently reported [8].
Vascular endothelial growth factor (VEGF) represents
one of the most potent mediators of angiogenesis both
in vivo and in vitro. Beyond that, VEGF presents with
major pleiotropic properties. It has been identified to
regulate monocyte recruitment towards granuloma for-
mation, while its expression within sarcoid granuloma
through the flt receptor was perceived to be elevated
[11]. Nevertheless its exact role in disease pathogenesis
is still elusive and controversial [12]. Genetic poly-
morphisms of VEGF have been associated with disease
susceptibility and may explain discrepancies in VEGF
levels in sarcoidosis patients [11,13]. VEGF expression is
mediated by hypoxia inducible factor (HIF)-1a [14]. HIF-
1a is recognized as a master regulator of hypoxic signal-
ing by activating gene transcription of genes encoding
proteins mediating the cellular adaptive response under
hypoxic conditions [14-17]. Nevertheless, an inflamma-
tory microenvironment can trigger HIF-1a expression
even under normoxic conditions [18]. Our group impli-
cated for the first time HIF-1a in the pathogenesis of
IPF. We demonstrated an overexpression of HIF-1a and
its transcription genes involved in angiogenesis (VEGF)
and apoptosis (p53) mainly localized within alveolar epi-
thelium of the fibrotic lungs [19]. Further extending our
seminal observations, we have recently reported a down-
regulation of inhibitor of growth factor (ING)-4 in IPF
lung samples. ING4 is a potent suppressor of HIF-1a
that exerts a beneficial role in cancer invasion, migration
and metastasis by inhibiting cell proliferation and angio-
genesis [20-23].
Our recent observations triggered the idea that the
concept of "immunoangiostasis" could provide a reason-
able explanation for sarcoid granuloma formation.
Immunoangiostasis concept supports that an angiostatic
and avascular microenvironment may preserve the re-
sponsible infectious agent under dormant state, while at
the same time will facilitate its eradication by monocyte
recruitment [24,25]. We therefore utilized high-
throughput microarray technology and computerized
image analysis seeking to determine the expression of
HIF-1a-VEGF-ING4 axis in lung biopsy samples from
patients with sarcoidosis of stages II-III.
Patients and methods
Patients
A total of 37 patients with pulmonary sarcoidosis were
recruited in the study (Table 1). Diagnosis of sarcoidosis
was based the following criteria: 1) compatible clinical
and radiological picture, 2) the histological evidence of
non-caseating granulomas and 3) exclusion of other dis-
eases capable of producing a similar histological orclinical picture [3]. Approval of the Ethics Committee of
the Democritus University of Thrace, Greece was
obtained (reference number 1669/2010). Part of the
video assisted thoracoscopic (VATS) lung biopsy tissue
was used to establish a diagnosis and the rest were for-
malin fixed and paraffin embedded to be used for tissue
microarray construction. Twenty nine patients were of
radiological stage II, 22 were male and 17 were never-
smokers. Based on functional assessment patients had
mild-to moderate restrictive pattern with a mean forced
vital capacity (FVC): 72 ± 7%pred, forced expiratory
volume at 1s (FEV1): 77 ± 11%pred, an FEV1/FVC: 85
± 13, a total lung capacity (TLC): 64 ± 10%pred, and a
moderate gas transfer impairment as estimated by dif-
fusing lung capacity for carbon monoxide (DLCO): 69
± 9%pred. Twenty four control paraffin blocks obtained
from the normal part of lungs removed for benign
lesions were collected from the archives of the Depart-
ment of Pathology of Veterans Hospital, Athens, Greece.
Methods
Quantitative Real-Time reverse transcriptase-polymerase
chain reaction (qRT-PCR)
qRT-PCR was performed using the Chromo 4 Real-Time
Detection System and the PlatinumW SYBRW Green
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lung tissue samples and 10 control lung samples
obtained during surgical removal of benign lesions of
the lung, according to the manufacturer's instructions. The
program used included: 2 min at 50°C, 5 min at 95°C, 43
cycles of denaturation-annealing- extension (30s at 95°C;
45s at 56°C; 30s at 72°C) and a final extension of 5 min at
72°C. Primers were chosen from exons separated by large
introns (spanning exonexon junctions), and the PCR qual-
ity and specificity was verified by melting curve analysis
and gel electrophoresis. Human (h) primer sequences (s:
sense, as: antisense) and expected lengths (in bp) were as
follows (5' to 3'): ING4 (s: AGC TTG CCA TGC AGA
CCT; as: GCG CAC GAG CTT TAA CTT; 245 bp) B2M
(s: CTG ACC CTA CAT TTT GTG CAT AAA AGATG
AGT ATG CC; as: ACC CTA CAT TTT GTG CAT AA;
202 bp). HIF-1A (s: GAA AGC GCA AGT CTT CAA AG;
as: TGG GTA GGA GAT GGA GAT GC; bp). VEGF (s:
CTA CCT CCA CCA TGC CAA GT; bp) Cycle threshold
(Ct; the first cycle that amplification can be detected)
values were obtained from the Opticon monitor 3 soft-
ware for each gene of interest and the control reference
gene, together with amplification efficiencies (85–115%).
Ct values were normalized to the reference gene beta-2-
microglobulin (B2M) [14].
Tissue microarrays
A total of 61 lung tissue samples including 37 sarcoid-
osis and 24 control tissues extracted from the normal
part of the lung removed for benign lesions were snap
frozen and stored at 70°C. Specimens were fixed in cold-
ethanol for 16 h and then embedded in paraffin.
Hematoxylin and eosin (H&E) –stained slides were used
from each block to define the regions characterized by
granulomatous lesions. Areas of interest were verified in
H&E stained slides by using a conventional microscope
(Olympus BX-50). Tissue cylinders of 1.5 mm diameter
were punched from selected areas of each "donor" block
by utilizing a thin-wall stainless tube from a precision
instrument (TMA-100, Chemicon, USA) and were trans-
ferred by a solid stainless stylet into defined array coor-
dinates in a 45 * 20 mm new recipient paraffin block
(citation 17 from ING paper). The tissue microarray
blocks were constructed in three copies (each containing
one sample from a different region of all lesions). One
sample was taken from the centre and two samples from
different peripheral areas. Ultimately, we created two tis-
sue microarray blocks comprising of 60 tissue elements
each. Each tissue element in the array was 1.5 mm in
diameter and spacing between two adjacent elements
was 0.1 mm. After the tissue microarray construction 3
μm sections for immunohistochemical analysis were cut
from the "donor" blocks and were transferred to glass
slides using an adhesive-coated tap sectioning system.Immunohistochemistry
Immunohistochemistry was performed by using specific
monoclonal antibodies for HIF-1a (HIF-1a-rabbit anti-
human antibody, Abcam Lim), VEGF for 121, 165 and
189 isoforms, and ING4 (anti-h-ING4 rabbit polyclonal
unconjugated antibody (10617-1-AP-Proteintech Group,
Inc., Chicago, IL, USA). The slides were deparaffinised
and En Vision immunohistochemistry protocol (DAKI
corp, Denmark) was carried through the use of an auto-
mated immunohistochemistry staining system (Bond-
Biogenex, USA). Diaminobenzidine (DAB) was used as
chromogenic substrate. This immunohistochemistry
protocol is based on a water-soluble, dextran polymer
system preventing the endogenous biotin reaction, which
is responsible for the background in the stained slides.
More specifically, the sections were incubated with the
primary antibody in "antibody diluent" (DAKO) and
goat-anti-mouse EnVision- HRP-enzyme conjugate was
performed for 3 min each. The "highly sensitive 3,3,' dia-
minobenzidine plus" (DAB+) and the "3- amino-9-
ethylcarbazol plus" (AEC+) chromogens (both from
DAKO) were used as substrates for the EnVision- HRP-
enzymes. Staining intensity was further enhanced by
modifying the manufacturer's protocol in that all incuba-
tion steps (primary antibodies, EnVision, and substrate
reactions) were performed on slides placed horizontally
on a thermal plate at 37C. After each incubation the
slides were dipped in TBS or, after the substrate reac-
tion, in tap water at RT and waved at maximum speed
for 10 sec. Excess liquid (buffer/water) was soaked up by
a paper towel. Specimens of colon adenocarcinoma cases
were used as positive controls for the marker.Computerized image analysis
In order to evaluate the immunohistochemistry results
not in a qualitative way but in a more accurate and reli-
able way, we performed computerized image analysis, in
all tissue microarray samples (n=61), by using a semi-
automated system (Matrox II Card Frame Grabber,
Camera Microwave Systems, Microscope Olympus BX-
50) allowing us to assess staining intensity in a 256 level
scale – 0 (black)-255(white). Staining intensity values
were then converted to reverse percentages [reverse
staining intensity = (1-staining intensity/256) ×100].Statistical analysis
Statistical analysis was carried out using SPSS 14.0 soft-
ware. Results are expressed as mean ± SD, or median
(range), unless otherwise indicated. Statistical signifi-
cance was verified by performing independent samples
t-test to compare reverse staining intensity and qRT-
PCR values of HIF-1a and VEGF-ING4 between patients
and controls. Results were corrected using Bonferroni
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tically significant.
Results
Absence of HIF-1a expression within sarcoid granulomas
HIF-1a was found to be minimally expressed within sar-
coid granulomas when compared to control lung samples.
Specifically, qRT-PCR in 10 sarcoidosis lung tissue sam-
ples revealed a downregulation of HIF-1a expression both
in protein and mRNA level, compared to 10 controls, as
shown in Figure 1A. To authenticate the above procedure,
tissue microarray sections were stained with monoclonal
HIF-1a antibody and demonstrated diffuse cytoplasmic re-
action of weak intensity within granuloma (Figure 2A-D)
compared to control specimens (Figure 2E). Results were
further corroborated and quantified by computerized
image analysis (Figure 2F)Figure 1 HIF-1a, Vegf and Ing4 mRNA expression levels in sarcoidosis
quantified by qRT-PCR showed a statistically significant incline and decline
samples (n=10). All values were normalized with the reference gene B2m. *Abudant VEGF expression within sarcoid granulomas
VEGF expression profile followed that of its master regu-
lator, namely HIF-1a. In particular, qRT-PCR in 10 sar-
coidosis and 10 control lung samples revealed abundant
VEGF expression (Figure 1B) in sarcoidosis mediastinal
lymph nodes compared to controls evidence that was fur-
ther corroborated by semi-quantitative computerized
immunohistochemistry analysis in tissue microarray sec-
tions of sarcoidosis patients revealing a diffuse cytoplas-
mic strong staining intensity, indicating increased VEGF
expression (Figure 3A-F).
Increased ING4 expression within sarcoid granulomas
The expression pattern of ING4 within fibrotic lungs [20]
was inversely related with that of HIF-1a, as has previ-
ously been demonstrated [19], suggesting a role for this
transcription factor during disease pathogenesis. In linelung samples. Hif-1a (A), Vegf (B) and Ing4 (C) gene expression levels
in sarcoidosis lung tissue samples (n=10) compared to control lung
p < 0.05.
Figure 2 HIF-1a immunohistochemical staining in sarcoidosis lung samples. Representative tissue microarray section immunostained with
monoclonal antibody HIF-1a demonstrating diffuse cytoplasmic reaction of weak intensity in epithelioid cells within granulomas (arrows) derived
from sarcoidosis patients (n=37) compared to control lung samples (n=24) (E). Scale bars in panel A: 100μm, B and C: 25 μm and D, E: 10 μm.
Immunohistochemical findings were confirmed by computerized image analysis (F).
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mRNA levels were extensively expressed in areas of
diminished HIF-1a expression, as assessed by qRT-PCR
(Figure 1C), and tissue microarray immunohistochemical
computerized image analysis, respectively. The latter
starkly demonstrated positively stained epithelioid cells
within sarcoid tissue samples with patchy distribution
and strong intensity compared to control lung samples
(Figure 4A-F).
Discussion
To the best of our knowledge this is the first study in
the literature investigating the expression of HIF-1a-
VEGF-ING4- axis in sarcoidosis patients. High-
throughput tissue microarray technology coupled with
qRT-PCR, immunohistochemistry and computerized
image analysis were applied to lung and lymph nodes bi-
opsy samples from sarcoidosis patients and controls.
Our results revealed a diminished expression, both inprotein and mRNA level of HIF-1a within sarcoid granu-
lomas and abundant expression of VEGF and ING4,
mainly localized in epithelioid cells within granuloma-
tous tissue.
HIF-1a expression represents the first step of cellular
response to hypoxia, leading to the transcription of sev-
eral genes involved in angiogenesis, apoptosis, cellular
differentiation and proliferation as well as energy metab-
olism [14-16]. Until recently, its role in the pathogenesis
of fibroproliferative lung disorders, including IPF has
been severely underscored by the lack of sufficient evi-
dence to support its role in fibrogenesis. Our study
group seminally reported an early overexpression of
HIF-1a during disease course both in the experimental
model of pulmonary fibrosis and in actual human dis-
ease. Thus, suggesting that HIF-1a activation can repre-
sent an early event and a potential fibrotic stimulus [19].
HIF-1a activation can also be triggered by several in-
flammatory and immunomodulatory factors including
Figure 3 VEGF immunohistochemical staining in sarcoidosis lung samples. Representative immunohistochemically stained tissue microarray
section with monoclonal antibody against VEGF demonstrates diffuse cytoplasmic stain of moderately strong intensity in epithelioid cells within
granulomas (arrows) derived from sarcoidosis patients (n=37) compared to control lung samples (n=24). Scale bars in panel A: 100μm, B and C:
25 μm and D, E: 10 μm. Immunohistochemical findings were confirmed by computerized image analysis (F).
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(TNFa) [14,16,18]. Its expression is tightly regulated not
only by changes in cellular O2 concentration [26] but
can be inhibited by several growth factors including
ING4 [23,27]. The latter seems to inhibit angiogenesis
through interaction with HIF proly hydroxylases (HPH)
and RelA subunit of NF-κΒ resulting in downregulation
of HIF activation and repression of angiogenesis related
genes including IL6, IL-8 and Cox2, respectively [23,27].
Sarcoidosis represents a disease paradigm with a pre-
dominance of the Th1 response in its immunopathogen-
esis [6]. The past years have seen the emergence of Th1
mediators such as CXCR3/CXCR3 ligands (interferon
gamma regulated CXC chemokines) as factors leading to
granuloma formation, the pathogenetic hallmark ofsarcoidosis. These mediators have pleiotropic properties
including inhibition of angiogenesis, monocyte recruit-
ment and T cell migration to sites of ongoing inflamma-
tion [5-7,25]. In addition our study group demonstrated a
distinct angiogenic and angiostatic profile between patients
with IPF and sarcoidosis, further supporting the role of
angiogenesis and its mediators in chronic lung disorders [8].
Despite these data there is pivotal lack of knowledge
regarding the expression and the immunolocalization of
the master regulator of angiogenesis HIF-1a and its
related genes within the sarcoid granuloma. Therefore
we applied the pioneering technology of tissue microar-
rays, which allowed us the simultaneous analysis of up
to 61 lung samples from sarcoidosis patients and con-
trols in a single experiment under highly standardized
Figure 4 ING4 immunohistochemical staining in sarcoidosis lung samples. Representative immunohistochemical staining with monoclonal
antibody against ING4 shows positively stained epithelioid cells within within granulomas (arrows) derived from sarcoidosis patients (n=37)
compared to control lung samples (n=24). Scale bars in panel A: 100μm, B and C: 25 μm and D, E: 10 μm. Immunohistochemical findings were
confirmed by computerized image analysis (F).
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in an identical, unbiased fashion, with minimal tissue
damage and precise positioning of arrayed samples,
which served as an ideal basis for computerized image
analysis of immunohistochemistry findings amenable to
robust statistics. We identified a diminished expression
of HIF-1a both in protein and mRNA level within sar-
coid granuloma whereas an abundant expression of
VEGF by epithelioid and giant cells in was also noted
within granulomatous tissue. Furthermore to gain a hol-
istic view regarding the hypoxia-angiogenesis axis within
granulomatous lesions in sarcoidosis patients we investi-
gated the expression of HIF-1a repressor gene, ING4.
Immunohistochemistry and computerized image analysis
revealed a strong staining intensity of ING4 inepithelioid cells within sarcoid granuloma, evidence that
was further corroborated by elevated levels of mRNA, as
assessed by qRT-PCR.
The impairment of the HIF-1a-VEGF axis may have
dual explanation. Current data support the notion of an
avascular micro-environment within sarcoid lesions [29].
Thus, it is conceivable to speculate that VEGF abundant
expression may be implicated more in the inflammatory
cascade of sarcoidosis rather than the angiogenic one.
This is supported by the pleiotropic properties of VEGF
to promote Th1-dependent immunity through facilita-
tion of monocyte recruitment and T-cell migration to
sites of ongoing inflammation [11,30].
An alternative explanation is that HIF-1a depreciated
expression maybe attributed to the specific timepoint
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significant limitation of pathology studies is that the pre-
sented findings simply represent a snapshot of disease
pathogenesis and by no means do they mirror the entire
pathogenetic cascade. It is therefore impossible to con-
clude a causal-effect relationship between decline of
HIF-1a expression and upregulation of VEGF and ING4
since HIF-1a may have been simply consumed and
exerted its functions by the time diagnosis of sarcoidosis
was established based on tissue findings. In line with
this, based on the descriptive nature of our study, we
cannot draw definite conclusions with regards to HIF-1a
and ING4 contribution to immunoangiostasis. HIF-1a
promotes angiogenesis through the transcription of vari-
ous mediators, including VEGF which was found to be
abundantly expressed inside granulomas. However, this
notion deserves further investigation, since HIF-1a initi-
ates a cascade of angiogenesis involving the activation of
several transcriptional genes beyond VEGF.
Conclusions
In sum, our data exhibit for the first time in literature a
downregulation of HIF-1a within sarcoid granulomas,
coupled with VEGF and ING4 upregulation. Reduced ac-
tivity of HIF-1a due to ING4 overexpression may pro-
mote an angiostatic environment within granulomas,
while VEGF could be responsible for macrophage
chemotaxis. Our results represent the first attempt in
the literature investigating the expression and immuno-
localization of HIF-1a-VEGF-ING4 axis within sarcoid
lesions shedding further light in the understanding of
the pathogenesis of sarcoidosis, favoring the infectious
etiology concept. More studies exploring the contribu-
tion of immunoangiostasis to the development of granu-
lomas are urgently needed.
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